Effects of p38 MAPK inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 6, 2007, Pages 362-368

  Bao, Weike ^a   Behm, David J ^a   Nerurkar, Sandhya S ^a   Ao, Zhaohui ^a   Bentley, Ross ^a   Mirabile, Rosanna C ^a   Johns, Douglas G ^a   Woods, Tina N ^a   Doe, Christopher P A ^a   Coatney, Robert W ^a   Ohlstein, Jason F ^a   Douglas, Stephen A ^a   Willette, Robert N ^a   Yue, Tian Li ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Angiotensin II; NADPH oxidase; p38 MAP kinase; Superoxide anion

Indexed keywords

4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ANGIOTENSIN II; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL INJURY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; AORTA, ABDOMINAL; BLOOD PRESSURE; CAROTID ARTERIES; ECHOCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HYPERTENSION; IMIDAZOLES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MYOCARDIUM; NADPH OXIDASE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDES; VASODILATION; VENTRICULAR REMODELING;

EID: 34347247586     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318046f34a     Document Type: Article

References (26)

1. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11-34.
2. Ushio-Fukai M, Alexander RW, Akers M, et al. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem. 1998;273:15022-15029.
3. Zhang GX, Kimura S, Nishiyama A, et al. ROS during the acute phase of Ang II hypertension participates in cardiovascular MAPK activation but not vasoconstriction. Hypertension. 2004;43:117-124.
4. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
5. Sugden PH, Clerk A. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res. 1998;83:345-352.
6. Ju H, Behm DJ, Nerurkar S, et al. p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Ther. 2003;307:932-938.
7. Li JM, Gall NP, Grieve DJ, et al. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 2002;40:477-484.
8. Brandes RP, Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res. 2005;65:16-27.
9. Cuzzocrea S, Mazzon E, Dugo L, et al. Superoxide: a key player in hypertension. Faseb J. 2004;18:94-101.
10. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
11. Parinandi NL, Kleinberg MA, Usatyuk PV, et al. Hyperoxia-induced NAD(P)H oxidase activation and regulation by MAP kinases in human lung endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2003;284:L26-38.
12. Lal AS, Clifton AD, Rouse J, et al. Activation of the neutrophil NADPH oxidase is inhibited by SB 203580, a specific inhibitor of SAPK2/p38. Biochem Biophys Res Commun. 1999;259:465-470.
13. Yamamori T, Inanami O, Nagahata H, et al. Roles of p38 MAPK, PKC and PI3-K in the signaling pathways of NADPH oxidase activation and phagocytosis in bovine polymorphonuclear leukocytes. FEBS Lett. 2000;467:253-258.
14. Higashi M, Shimokawa H, Hattori T, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res. 2003;93:767-775.
15. Delbosc S, Cristol JP, Descomps B, et al. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension. 2002;40:142-147.
16. Widder J, Behr T, Fraccarollo D, et al. Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent. Cardiovasc Res. 2004;63:161-167.
17. Meloche S, Landry J, Huot J, et al. p38 MAP kinase pathway regulates angiotensin II-induced contraction of rat vascular smooth muscle. Am J Physiol Heart Circ Physiol. 2000;279:H741-751.
18. Elmarakby AA, Loomis ED, Pollock JS, et al. NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1. Hypertension. 2005;45:283-287.
19. Skatchkov MP, Sperling D, Hink U, et al. Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production. Biochem Biophys Res Commun. 1999;254:319-324.
20. Behm DJ, Herold CL, Ohlstein EH, et al. Pharmacological characterization of SB-710411 [Cpa-c(D-Cys-Pal-D-Trp-Lys-Val-Cys)-Cpa-amide], a novel peptidic urotensin-II receptor antagonist. Br J Pharmacol. 2002;137:449-458.
21. Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR. Genome Res. 1996;6:986-994.
22. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
23. Ge B, Gram H, Di Padova F, et al. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science. 2002;295:1291-1294.
24. Hirooka Y, Eshima K, Setoguchi S, et al. Vitamin C improves attenuated angiotensin II-induced endothelium-dependent vasodilation in human forearm vessels. Hypertens Res. 2003;26:953-959.
25. Ulker S, McKeown PP, Bayraktutan U. Vitamins reverse endothelial dysfunction through regulation of eNOS and NAD(P)H oxidase activities. Hypertension. 2003;41:534-539.
26. Rey FE, Cifuentes ME, Kiarash A, et al. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res. 2001;89:408-414.